Diaceutics PLC represents a strong commitment to revolutionizing patient testing in the global diagnostic industry. The company's corporate philosophy is rooted in driving better patient outcomes by improving diagnostic testing for precision medicine. With a focus on leveraging data analytics and deep industry knowledge, Diaceutics PLC aims to bridge the gap between diagnostic testing and targeted therapies. By partnering with pharmaceutical companies, laboratories, and healthcare providers, Diaceutics PLC strives to enable faster and more accurate testing to ensure patients receive the right treatment at the right time. Through innovation, collaboration, and patient-centricity, Diaceutics PLC is dedicated to empowering precision medicine and transforming healthcare.

Diaceutics PLC is primarily present in multiple countries and regions worldwide. The company operates globally, with a strong presence in the United States, Europe, and key Asian markets. This includes countries such as the United Kingdom, Germany, France, Spain, Italy, China, Japan, and Australia, among others. With its expansive reach, Diaceutics PLC caters to healthcare providers, pharmaceutical companies, and diagnostic laboratories in various regions, enabling better personalized medicine and improving patient outcomes.

Diaceutics PLC, a leading diagnostic data analytics and implementation services provider, has achieved several significant milestones. Firstly, the company successfully listed on the AIM market of the London Stock Exchange in March 2019, marking a major achievement in terms of financial market recognition. Additionally, Diaceutics has experienced substantial growth, expanding its global reach and establishing strategic partnerships with renowned pharmaceutical companies. Moreover, the company has received multiple awards and recognition for its innovative and impactful contributions to precision medicine. Diaceutics PLC's remarkable achievements are a testament to its commitment to revolutionizing the way healthcare providers utilize diagnostic testing, ultimately improving patient outcomes.

Diaceutics PLC is a leading data analytics and implementation services provider in the personalized medicine industry. Founded in 2005, the company has grown steadily and garnered a strong reputation for its expertise in diagnostic testing. It enables pharmaceutical companies, laboratories, and healthcare providers to optimize the use of targeted therapies for patients by leveraging advanced data analytics. Diaceutics PLC's robust platform helps bridge the gap between diagnostic testing and personalized medicine, significantly improving patient outcomes. With its deep industry knowledge and proprietary data-driven solutions, the company has become a trusted partner for life science companies globally, unlocking the potential of precision medicine.

The main competitors of Diaceutics PLC in the market include companies such as LabCorp, QIAGEN, Foundation Medicine, and Genomic Health.

Diaceutics PLC is primarily active in the healthcare and pharmaceutical industries. As a leading diagnostic commercialization company, Diaceutics specializes in helping pharmaceutical companies and laboratories improve patient outcomes through the delivery of precision medicine. With their extensive expertise in data analytics and laboratory network management, Diaceutics empowers healthcare providers to effectively integrate diagnostic testing into patient treatment pathways, thereby enhancing personalized medicine.

The business model of Diaceutics PLC focuses on providing personalized diagnostics solutions and services to the pharmaceutical industry. Diaceutics helps pharmaceutical companies and laboratories optimize their diagnostic testing processes, ensuring patients receive accurate and timely test results. By harnessing real-world data and leveraging their expertise in diagnostic commercialization, the company enables precision medicine and improves patient outcomes. With a comprehensive approach that includes strategic consulting, data analytics, and software solutions, Diaceutics aims to bridge the gap between diagnostic testing and the delivery of targeted therapies.

Rasio P/E Diaceutics adalah -64,77.

Rasio KUV dari Diaceutics adalah 3,28.

Skor Kualitas AlleAktien untuk Diaceutics adalah 3/10.

Omset diharapkan Diaceutics adalah 30,14 Juta. GBP.

Laba diharapkan Diaceutics adalah -1,53 Juta. GBP.

Diaceutics PLC is an international company specializing in improving the diagnostics and care of cancer patients. The company's business model is based on the use of data analysis to understand the connections between diagnostics, therapy, and patient outcomes in order to optimize cancer treatment.

Diaceutics membayarkan dividen sebesar 0 GBP yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Diaceutics saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Diaceutics adalah GB00BJQTGV64.

WKN dari Diaceutics adalah A2PF80.

Ticker dari Diaceutics adalah DXRX.L.

Dalam 12 bulan terakhir, Diaceutics membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Diaceutics diperkirakan akan membayar dividen sebesar 0 GBP.

Imbal hasil dividen dari Diaceutics saat ini adalah .

Diaceutics membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Diaceutics membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 GBP. Ini setara dengan yield dividen sebesar 0 %.

Diaceutics dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Diaceutics tanggal 23/11/2024 sejumlah 0 GBP, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 23/11/2024.

Pembayaran dividen terakhir dilakukan pada 23/11/2024.

Pada tahun 2023, Diaceutics 0 GBP telah dibayarkan sebagai dividen.

Dividen dari Diaceutics dibayarkan dalam GBP.